A Look Into Gilead Sciences Inc’s Price Over Earnings
Looking into the current session, Gilead Sciences Inc. (NASDAQ:GILD) shares are trading at $79.44, after a 0.10% increase.…
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Tuesday, the FDA said it received reports of patients developing T-cell malig
Looking Into Gilead Sciences’s Recent Short Interest
Gilead Sciences’s (NYSE:GILD) short percent of float has fallen 4.37% since its last report. The company recently reported…
FDA Approves AstraZeneca’s Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead’s Drug
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or
Gilead Sciences’s Options: A Look at What the Big Money is Thinking
Financial giants have made a conspicuous bearish move on Gilead Sciences. Our analysis of options history for Gilead…
A Closer Look at Gilead Sciences’s Options Market Dynamics
Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences (NASDAQ:GILD), and it’s something market players shouldn’t ignore.…
Where Gilead Sciences Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Gilead Sciences (NASDAQ:GILD) stock. These analysts…
Gilead Sciences Stock Slides After Hours On Q3 Report – Here’s Why
Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's after-hours session on the heels of the company's
Positive News For Gastric Cancers – Gilead/Arcus Biosciences’ Combination Cancer Therapy Shows Encouraging Clinical Activity
Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month progress
S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto
Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum.